β5i-IN-2
β5i-IN-2 is a potent, selective, and orally active inhibitor of the immunoproteasome β5i subunit, with an IC50 of 0.08 μM against human β5i. β5i-IN-2 inhibits LPS (HY-D1056)- and IFN-γ-induced expression of IL-1β, IL-6, and TNF-α, and suppresses the JNK, ERK, and NF-κB signaling pathways. β5i-IN-2 can be used in research related to rheumatoid arthritis and ulcerative colitis.
For research use only. We do not sell to patients.
- CAS No.: 3119216-05-3
- Formula: C33H46N4O12
- Molecular Weight:690.74
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
β5i 0.08 μM (IC50) |
In Vitro
β5i-IN-2 (compound ent-F10) (1 μM; serial dilutions; 10-15 min) potently and selectively inhibits the immunoproteasome β5i in cell-free lysate and purified proteasome assays, with an IC50 of 0.08 μM, and a selectivity index of 123.8 over the constitutive proteasome β5[1].
β5i-IN-2 exhibits low affinity for hERG ion channels in HEK293 cells, indicating a low risk of cardiotoxicity[1].
β5i-IN-2 (10-40 nM; pre-treatment for 1 h) reduces the mRNA expression of IL-1β, IL-6 and TNF-α in RAW 264.7 cells in a concentration-dependent manner after stimulation with LPS (100 ng/mL) and IFN-γ (20 ng/mL) for 24 h[1].
β5i-IN-2 (10-40 nM; 4 h pre-treatment) reduces JNK and ERK phosphorylation in RAW 264.7 cells in a concentration-dependent manner following 15 min of stimulation with LPS and IFN-γ, and restores IκBα protein levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW 264.7 murine macrophage cells
-
Concentration:10, 20, 40 nM
-
Incubation Time:1 h (pretreatment); 24 h (stimulation)
-
Result:Concentration-dependently reduced IL-1β, IL-6 and TNF-α mRNA expression.
-
Cell Line:RAW 264.7 murine macrophage cells
-
Concentration:10, 20, 40 nM
-
Incubation Time:4 h (pretreatment); 15 min (stimulation)
-
Result:Reduced p-JNK and p-ERK levels and increased IκBα protein levels, with the strongest effects at 40 nM.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (SD) rats (rheumatoid arthritis CIA model, arthritis index ≥2 at study start)[1]
-
Dosage:2.5 mg/kg; 5.0 mg/kg; 10.0 mg/kg
-
Administration:p.o.; once daily; 14 days
-
Result:Dose-dependently reduced arthritis progression.
Day-14 arthritis index values were 7.13, 5.25, and 4.75 at 2.5, 5, and 10 mg/kg, respectively.
Produced paw-swelling inhibition rates of 17.2%, 32.3%, and 48.4%, respectively, on day 14, without significant body-weight loss.
Chemical Information
-
CAS No. 3119216-05-3
-
Molecular Weight 690.74
-
Formula C33H46N4O12
-
SMILES
O=C(N[C@@H](C)C(N[C@H](C(N[C@@H](C/C=C(C)/C)C([C@@]1(C)CO1)=O)=O)[C@H](O)C2=CC=C(OC)C=C2)=O)CN3CCOCC3.OC(/C=C\C(O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)